Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.

Dermatitis : contact, atopic, occupational, drug·2023
Same author

Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Patch Testing to Paraphenylenediamine: The North American Contact Dermatitis Group Experience (1994-2018).

Dermatitis : contact, atopic, occupational, drug·2023
Same author

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.

Dermatology and therapy·2023
Same author

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry.

Dermatology and therapy·2023
Same author

Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.

Allergy·2023

Related Experiment Video

Updated: Mar 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Phototherapy for atopic dermatitis.

Dorothy L Rodenbeck1, Jonathan I Silverberg2, Nanette B Silverberg3

  • 1Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL.

Clinics in Dermatology
|September 18, 2016
PubMed
Summary
This summary is machine-generated.

Phototherapy, a second-line treatment for atopic dermatitis (AD), effectively reduces skin inflammation. Various phototherapy methods exist, but access and side effects can limit treatment for chronic AD.

More Related Videos

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.0K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.0K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.3K

Area of Science:

  • Dermatology
  • Photomedicine

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition.
  • Phototherapy is a recognized second-line treatment for moderate to severe AD.
  • It is often used for cases unresponsive to topical therapies.

Purpose of the Study:

  • To review various phototherapy modalities for treating atopic dermatitis.
  • To discuss the efficacy, limitations, and adverse effects of different phototherapy approaches.
  • To examine dosing regimens and treatment concerns associated with phototherapy for AD.

Main Methods:

  • Review of six phototherapy approaches for atopic dermatitis.
  • Broadband ultraviolet B (UVB)
  • Narrowband UVB
  • Excimer lasers
  • Combination UVA/UVB
  • UVA-1
  • Goeckerman regimen (coal tar + broadband UVB)

Main Results:

  • Phototherapy effectively decreases cutaneous inflammation in AD.
  • Various methods offer different treatment options for specific needs.
  • Treatment is limited by inconvenience, access, adherence challenges, and potential adverse effects like skin cancer risk.

Conclusions:

  • Phototherapy is an effective treatment option for moderate to severe atopic dermatitis.
  • Careful consideration of treatment modalities, dosing, and potential side effects is crucial.
  • Patient convenience and adherence remain significant factors in successful phototherapy outcomes.